Opioid use disorder — MCCQE Part 1 MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Offer behavioural treatment and harm-reduction support
There is no medication currently approved by Health Canada specifically for methamphetamine use disorder. Initial care should engage the patient in evidence-informed behavioural treatment, such as cognitive-behavioural, motivational, and contingency-management approaches where available, while addressing housing, sleep, nutrition, infectious risk, cardiovascular symptoms, and safer-use practices. Co-occurring depression, psychosis, ADHD, and other substance use require assessment and treatment. Emerging or off-label pharmacotherapies may be considered by experienced clinicians after shared discussion of limited evidence, but none should be presented as an approved universal first-line drug. Detoxification alone does not provide sustained treatment, opioid agonist therapy treats coexisting OUD rather than stimulant use by itself, and abstinence must not be a prerequisite for respectful care or harm reduction.
Reference: Canadian Research Initiative in Substance Matters, ASCME: https://crism.ca/ascme/